This post examines the Lee Pharma v. AstraZeneca case on compulsory licensing under Indian patent law. The Controller’s decision sheds light on the standards for proving public need, affordable pricing, and working of patents in India.
Read more about Lee Pharma v. AstraZeneca- An unfinished Patent StoryTag: SAXAGLIPTIN
Astrazeneca to retain Sweetness of Onglyza
Astrazeneca has brought a patent infringement case against Aurobindo Pharma over an ANDA filing for Onglyza’s generic version in the US. The dispute centres on the alleged infringement of Saxagliptin hydrochloride patents before their expiry.
Read more about Astrazeneca to retain Sweetness of Onglyza